IMHONVAX will retrace to 52 week lows for a double bottom before ER...of course, post ER performance depends on Q3 earnings which are trending in the wrong direction.
I suggest you monitor Novavax from the sidelines until we see positive late-stage data from its remaining infectious-disease studies.